共查询到20条相似文献,搜索用时 184 毫秒
1.
血清CYFRA21—1免疫放射分析在非小细胞肺癌诊断中的临床价值 总被引:3,自引:0,他引:3
CYFRA21-1是细胞角蛋白19的片段(CK19)。免疫放射法(IRMA)测定133例肺癌患者血清中CYFRA21-1水平,与血清神经元特异性烯醇化酶(NSE)作比较,初步观察了5例非小细胞肺癌患者血清CYFRA21-1在治疗过程中的动态变化。结果表明肺癌患者血清CYFRA21-1水平明显高于肺良性疾患组和正常对照组;在肺癌患者,血清CYFRA21-1水平升高主要出现在非小细胞肺癌组,尤其鳞癌组 相似文献
2.
血清CYFRA21—1在肿瘤诊断中的临床价值 总被引:1,自引:0,他引:1
目的:探讨CYFRA21-1在肺癌、喉癌和消化道肿瘤中的诊断价值。方法:应用酶联免疫方法对82例肺癌、18例喉癌和74例消化道肿瘤测试血清CYFRA21-1水平。结果:①肺癌CYFRA21-1阳性率为79.3%,特异性为92.5%,准确率为83.6%,明显高于其他肿瘤;②肿瘤转移患者血清CYFRA21-1水平明显高于未转移患者;③肺癌治疗前后血清CYFRA21-1水平有显著差异,治疗后明显下降;④ 相似文献
3.
CYFRA21—1等肿瘤标记物在肺癌诊断中的应用 总被引:10,自引:0,他引:10
CYFRA21┐1等肿瘤标记物在肺癌诊断中的应用马兰艾桂萍许佩珉高德芹细胞角质蛋白19(CYFRA21-1)是一种新的肿瘤标志物,在肺癌组织中含量较高,并可溶于血清中,可借助两个单克隆抗体用酶联免疫法测定。我们以CYFRA21-1与癌胚抗原(CEA)... 相似文献
4.
CYFRA21-1在肺癌诊断、疗效监测及预后观察的临床意义 总被引:20,自引:0,他引:20
目的:研究CYFRA21-1在肺癌诊断、疗效监测和预后观察的临床意义及应用价值。方法:选自本院的327例肺癌,297例肺部良性疾病的住院和门诊病人应用放射免疫分析法(IRMA)检测了CYFRA211的血清水平。结果:肺癌组水平169±84ng/ml,非肿瘤组水平19±16ng/ml,(P<0001)差异显著。肺癌阳性率624%,良性疾病阳性率5%。测定灵敏度为624%特异性为945%,准确率779%。肺癌病人随病期的增加,血清CYFRA211含量也随之上升(P<002)。对8例肺癌手术病人和10例化疗病人含量变化分析,在手术3周~5周后,血清含量由术前的64±31ng/ml,降到18±06ng/ml,10例化疗病人,其中8例血清含量均有降低,临床证实均有良好的治疗效果,另2例临床证实治疗无效,血清CYFRA211水平相应增高。结论:血清CYFRA21-1的水平与肿瘤病人的临床表现有直接的相关性,提示测定肺癌患者血清CYFRA211水平对诊断和预后有重要的临床应用价值 相似文献
5.
血清CYFRA21—1,CEA和NSE联合检测对肺癌的诊断价值 总被引:9,自引:0,他引:9
血清CYFRA21┐1、CEA和NSE联合检测对肺癌的诊断价值李蓉李睿张哲舫研究已有标记物的有效联合检测,是目前肺癌肿瘤标记物的研究方向之一。为此,我们比较血清中细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)和神经元特异性烯醇化酶(NS... 相似文献
6.
乳腺癌患者血清CYFRA21—1检测的临床价值 总被引:2,自引:0,他引:2
目的:检测乳腺癌患者血清中CYFRA21-1水平,探讨其在乳腺癌的术前诊断和术后随访监测中的应用价值。方法:采用放免法测定34例乳腺良性疾病患者术前、47例乳腺癌患者术前和术后4周及56例乳腺癌术后随访患者的血清CYFRA21-1水平,进行对照分析。结果:乳腺良性疾病无1例阳性;乳腺癌术前阳性率仅21%,但两者血清CYFRA21-1水平有明显差异;47例乳腺癌患者手术前与术后4周血清CYFRA21-1水平相比有显著差异:56例乳腺癌患者术后随访例转移复发者中6例阳性,无转移复发者均阴性。转移复发者血清CYFRA21-1水平较无转移复发者明显增高,两者相比差异有极显著性。结论:血清CYFRA21-1检测对乳腺癌特异性高,但对乳腺癌术前诊断价值不大,对乳腺癌转移复发的监测有非常重要意义。 相似文献
7.
评价酶联免疫检测血清CYFRA21—1对非小细胞肺癌的诊断价值 总被引:8,自引:0,他引:8
目的评价检测CYFRA21┐1对非小细胞肺癌的诊断价值。方法用ELISA法测定70例肺癌(LC)其中47例非小细胞肺癌(NSCLC),3例小细胞肺癌(SCLC)和20例未分型肺癌、64例肺部良性疾病患者及40例健康人血清CYFRA21┐1浓度。试验的诊断性能用相对操作特征(ROC)分析法估测之。结果测得全阈诊断准确率(OveralDiag┐nosticAccuracies)LC为0.75、NSCLC为0.76,SQC为0.83,ADE为0.67和SCLC为0.38。在相应于特异性为0.95的界定值3.47μg/L处,各型的灵敏度分别为SQC0.62,LC0.53,NSCLC0.51,ADE0.48和SCLC0.00。结论结果显示CYFRA21┐1是NSCLC较灵敏和特异的一个标志物。未观察到TNM各期间该标志物的平均水平有明显的差异;然而异常升高水平的患者的比例随病期的进展而显著增加,提示一系列检测CYFRA21┐1水平可能有助于监查NSCLC患者的疗效。 相似文献
8.
CYFRA21—1,CEA联合测定对癌性胸水的诊断价值 总被引:13,自引:0,他引:13
检测118例胸水CYFRA21-1和CEA浓度以及ADA活性。其中癌性不67例,结核性胸水40例,其它良性渗漏液11例。CYFRA21-1对癌胸水的敏感度为62.6%,特异度为90.2%,CEA的敏感度为55.2%,特异度为100%。联合测定CYFRA21-1和CEA对癌性胸水的敏感度可提高到85.1%,其临床应用值值得重视。 相似文献
9.
[目的]观察胸水中肿瘤标志物测定值对临床诊断的价值。[方法]分别测定46例胸腔积液患者的血清与胸水肿瘤标志物(CEA、NSE、 CA242、 CYFRA21-1)含量,其中癌性积液28例,良性积液18例。[结果]发现胸水中肿瘤标志物含量明显高于血清水平;CEA、NES、CA242三者联合应用在胸水中敏感性高达92.8%,特异性96.2%,而血清中相应为75.1%,87.5%;CYFRA21-1在良性组中虽阳性率较高,但数值明显低于癌性积液组(P<0.01)。[结论]测定胸水肿瘤标志物对恶性积液的诊断具有临床应用价值。 相似文献
10.
11.
Hanagiri T Sugaya M Takenaka M Oka S Baba T Shigematsu Y Nagata Y Shimokawa H Uramoto H Takenoyama M Yasumoto K Tanaka F 《Lung cancer (Amsterdam, Netherlands)》2011,74(1):112-117
Purpose
This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.Subjects
This study evaluated 341 patients who had undergone a complete resection for stage I NSCLC between 2002 and 2008.Results
The patients included 193 males and 148 females. The mean age of the patients was 69.2 years (range: 19–88). The histological types included 264 adenocarcinomas, 56 squamous cell carcinomas, 11 large cell carcinomas, and 10 other types of carcinoma. A pneumonectomy was performed in 2 patients, a bilobectomy in 7, a lobectomy in 255, a segmentectomy in 46, and partial resection of the lung in 31 patients. The positive rates for CYFRA 21-1 in the adenocarcinoma and squamous cell carcinoma patients were 33.3% and 76.8%, respectively. The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively. The 5-year survival rate after surgery in the normal CYFRA 21-1 group and the high CYFRA 21-1 groups were 92.8% and 75.4%, respectively, in the patients with stage I NSCLC. There was a significant difference between the 2 groups (p < 0.0001). The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group. In a multivariate analysis using the variables found to be significant prognostic factors in univariate analysis, a high CYFRA 21-1 level was found to be a significant independent prognostic factor (95% confidence interval 1.213–5.442, p = 0.014).Conclusion
A high preoperative CYFRA 21-1 level was a significant independent prognostic factor in patients with stage I NSCLC. The patients with a high CYFRA 21-1 level should carefully followed-up to rule out occult metastasis. Further clinical studies will be necessary to evaluate the efficacy of adjuvant therapy for the patients selected according to this criterion. 相似文献12.
Nisman B Biran H Heching N Barak V Ramu N Nemirovsky I Peretz T 《British journal of cancer》2008,98(1):77-79
Prognostic implication of serum cytokeratin 19 fragments (CYFRA 21-1) was explored in 60 advanced NSCLC patients, whereas in 45 patients assessable for serological response a >or=35% CYFRA 21-1 decline after two chemotherapy cycles was strongly associated with non-progression (NP), defined as a sum of objective response (OR)+stable disease (P<0.0001) and survival (P=0.0002). Association of OR with survival was not significant. In multivariate survival analysis, >or=35% marker decline and radiological NP status were found as major determinants of prolonged survival with RR: 0.37 (P=0.01) and 0.63 (P=0.01), respectively. In advanced NSCLC patients, NP reflects therapeutic efficacy better than traditional OR. CYFRA 21-1 >or=35% decline seems to be a reliable surrogate marker of treatment efficacy in terms of survival. 相似文献
13.
J. Niklinski M. Furman T. Burzykowski L. Chyczewski J. Laudanski E. Chyczewska M. Rapellino 《British journal of cancer》1996,74(6):956-960
The CYFRA 21-1 assay is a test that has been developed recently for detection of a cytokeratin 19 fragment in serum. A diagnostic role for CYFRA 21-1 has already been proposed. The question of whether this marker is prognostically significant is important in clarifying the role of CYFRA 21-1 in clinical practice. The aim of this study was to evaluate the prognostic significance of elevated preoperative CYFRA 21-1 levels in patients with resected primary squamous-cell lung cancer (SqCC). Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 91 patients with operable SqCC. Survival and disease-free survival curves related to initial levels of this marker were estimated using the Kaplan-Meier method. In the univariate analysis the log-rank test and the log-rank test for trend were used. In the multivariate analysis the stratified log-rank test and the proportional hazard model were used. Elevated preoperative CYFRA 21-1 levels were identified in 55% of patients with SqCC. The number of patients with elevated levels of this marker increased with TNM stage (P = 0.0001). In univariate analysis elevated levels of CYFRA 21-1 were significantly associated with poor overall survival (P < 0.00005) and with disease-free survival (P < 0.00005). In multivariate analysis elevated levels of this marker were also found to be associated with poor overall and disease-free survival (P = 0.01 and P = 0.003 respectively). In conclusion, CYFRA 21-1 may be an independent prognostic parameter of survival and tumour relapse in SqCC and may be useful in identifying resected SqCC patients at high risk of treatment failure. 相似文献
14.
目的:探讨肺癌患者血清肿瘤标记物细胞角蛋白19片段(CYFRA21-1)与肿瘤病理类型和吸烟的相关性和对肺癌的诊断价值。方法:应用化学发光技术测定经病理确诊的187例肺癌患者、33例肺良性疾病和健康对照的CYFRA21-1水平。应用SPSS18统计软件包分析病理类型、吸烟和CYFRA21-1间的关系。结果:187例肺癌患者血清中CYFRA21-1水平明显高于非良性病和健康对照组,肺良性病与健康对照组比无显著差别;187例患者吸烟者123例(65.7%),不吸烟者64例(34.2%)。在肺鳞癌、肺腺癌及小细胞肺癌中,吸烟者分别为72.9%、52.3%和73.0%,各组间行卡方分析χ2=8.03 P=0.018;血清CYFRA21-1在鳞癌、腺癌和小细胞肺癌的水平分别为13.96±22.84、7.12±12.22、3.66±4.66,各组间有显著差别(F=5.58,P=0.004);阳性率分别为58.8%、38.5%和32.4%,χ2=9.82,P=0.007,但腺癌与小细胞癌比无显著差别。cfyra211阳性率在非吸烟组、轻、中、重度吸烟组分别为39.1%、61.5%、52.2%和43.0%,四组间阳性率有显著差别,以非吸烟组为最低,重度吸烟组次之(χ2=9.542 P=0.023)。结论:cfyra211在肺鳞癌、腺癌和小细胞癌中肺鳞癌的水平和阳性率最高;肺鳞癌和小细胞癌吸烟者占大多数,cfyra211水平与吸烟无明显的相关性,但对肺鳞癌的诊断有一定的价值。 相似文献
15.
Kashif Iqbal Yuan Chen Mengxian Zhang Qian Chu 《中德临床肿瘤学杂志》2007,6(3):P250-P253
Objective: In an era of ever evolving, promising new therapies for advanced non small cell lung cancer (NSCLC), early predictors of response to therapy, are needed. We evaluated early variations in CYFRA 21-1 serum levels of patients with advanced NSCLC receiving first line chemotherapy and correlated the results with objective tumor response. Methods: 29 consecutive, previously untreated, patients of advanced non small cell lung cancer, with measurable disease on CT scan were evaluated. All patients were treated with conventional systemic chemotherapy, although the choice of chemotherapy was left to the discretion of the treating physicians. Serum samples were obtained immediately before the start of 1st and 2nd cycles of chemotherapy. CYFRA 21-1 was measured with an electrochemiluminescense immunoassay on an automatic analyzer (Elecsys 2000; Roche Diagnostics). Response was evaluated using Response evaluation criteria in solid tumors (RECIST) criteria. Results: 10 patients had partial response, 9 patients had stable disease and 9 had progressive disease. None of the patients had complete response. 21/29 (72%) patients had an elevated baseline value of CYFRA 21-1. 62% pa- tients (18/29) had a decrease in CYFRA 21-1 after 1 cycle of chemotherapy. The average reduction in the 2nd reading was ir- respective of whether baseline value was normal or not. The average reduction was statistically significant (P = 0.002; 95% CI, from 0.8369 to 3.49464; t test). 8 out of 10 (80%) patients with partial response had a reduction in their 2nd reading of. CYFRA (P = 0.019; 95% CI, from 0.81965 to 7.20035; t test) which was significant. We also observed that 6/9 (66%) patients whose disease remains stable also had a decrease in their subsequent reading (P = 0.0106; 95% CI, from –0.44942 to 3.82720; t test), though it was not significant statistically. Although 5 out of 9 (55%) patients, who had an increase in their CYFRA 21-1 level, had progressive disease, but it was not statistically significant (P = 0.537; 95% CI, from –1.20021 to 2.13354; t test). 14 out of 19 (73%) who either had partial response or had stable disease, had a reduction in their 2nd value of CYFRA 21-1 and was significant statistically (P = 0.004; 95% CI, from 0.74792 to 3.50208; t test). We also observed that except for 1 patient, all patients who had a decrease of 42% or more in their subsequent CYFRA 21-1 level, were those who had either responded to chemotherapy or had stable disease (P = 0.001), which was statistically significant. Conclusion: We can conclude that monitoring of serum marker CYFRA 21-1, early during first-line chemotherapy may be a useful prognostic tool for evaluation of early tumor response in patients with advanced NSCLC. 相似文献
16.
血清肿瘤标志物在肺癌辅助诊断中的应用 总被引:24,自引:3,他引:21
目的探讨5种血清肿瘤标志物在肺癌辅助诊断中的应用价值,并选择最理想的血清肿瘤标志物组合。方法应用酶联免疫吸附实验(ELISA)检测170例肺癌患者、50例健康人和60例肺部良性疾病患者血清中神经元特异性烯醇化酶(NSE)、胃泌素释放肽前体(pro GRP)、细胞角蛋白19(CYFRA211)、p53抗体和癌胚抗原(CEA)的水平含量。结果肺癌患者的5种血清肿瘤标志物水平均明显高于健康人组和肺部良性疾病组,差异有统计学意义(P<0.01)。NSE、pro GRP在小细胞肺癌中的水平明显高于其他类型的肺癌(P<0.01),CYFRA211在鳞癌中的水平明显高于其他类型的肺癌(P<0.01)。p53抗体的特异性为100%,NSE、pro GRP对小细胞肺癌检测的敏感性明显高于其他类型的肺癌(P<0.01),CYFRA211对鳞癌检测的敏感性明显高于其他类型的肺癌(P<0.01)。5种血清肿瘤标志物经组合后,敏感性明显高于任一单项肿瘤标志物(P<0.01)。结论5种血清肿瘤标志物对于肺癌的辅助诊断有一定的临床意义。NSE、pro GRP二者可作为联合检测小细胞肺癌的首选标志物,CYFRA211、CEA和p53抗体三者可作为联合检测非小细胞肺癌的首选标志物。p53抗体对肺癌的辅助诊断有很高的特异性,CYFRA211对鳞癌的辅助诊断有一定的作用。 相似文献
17.
目的 对肺癌患者化疗前后外周血内肿瘤标志物水平改变进行分析.方法 随机选取50例肺癌患者,给予紫杉醇类或联合顺铂方案化疗2个周期,采用放射免疫技术对不同病理类型组化疗前后外周血内肿瘤标志物CEA、NSE、CYFRA 21-1水平进行监测,并结合化疗前后肺部CT影像学变化分析化疗前各病理类型血清肿瘤外周血内肿瘤标志物水平.结果 50例患者经2个周期化疗后,行CT影像学检测评估,肿块PR+ CR者38例,NC+ PD者12例.化疗前,腺癌组血清CEA水平显著高于鳞癌组和小细胞肺癌组;鳞癌组CYFRA 21-1水平显著高于腺癌组和小细胞肺癌;小细胞肺癌组NSE水平显著高于腺癌组和鳞癌组,数据对比差异均具有统计学意义(P<0.05).腺癌组(CR+ PR)化疗后CEA水平显著低于化疗前;鳞癌组(CR+ PR)化疗后CYFRA 21-1水平显著低于化疗前;小细胞肺癌组(CR+ PR)化疗后NSE水平显著低于化疗前,数据对比差异均具有统计学意义(P<0.05).结论 通过检测外周血内肿瘤标志物CEA、NSE、CYFRA 21-1水平改变可用于化疗疗效判定,具有简便、经济的特点. 相似文献
18.
目的:探讨联合检测肺癌胸水和血清中癌胚抗原(CEA)、癌抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)、神经原特异性烯醇化酶(NSE)和胃泌素释放肽前体(Pro-GRP)5 种肿瘤标志物水平在肺癌临床诊断中的应用价值,以期提高鉴别良恶性胸水的能力。方法:用电化学发光法检测93例肺癌患者和54例肺炎性疾病患者的血清及胸水标本CEA、CA125、CYFRA21-1、NSE和Pro-GRP水平。结果:癌性胸水组中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物平均水平与炎性胸水组比较,差别均有统计学意义(P<0.05);癌性胸水组中CEA、CYFRA21-1、CA125的含量远远高于炎性胸水组(20~600倍)(P<0.01)。肺癌胸水组中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物水平与肺癌血清组比较,差别均有统计学意义(P<0.05)。肺癌胸水组中CEA、CYFRA21-1、CA125的含量远远高于肺癌血清组(7~80倍)(P<0.01),相比与正常对照组更是有200倍以上的增高(P<0.01),因此胸水中CEA、CYFRA21-1、CA125百倍左右的升高提示恶性肿瘤的存在。将93例癌性胸水和血清分为腺癌、鳞癌和小细胞癌。腺癌、鳞癌和小细胞癌胸水组中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物含量明显高于炎性胸水组(P<0.01);腺癌胸水组中CEA含量明显高于鳞癌和小细胞癌(P<0.01);鳞癌胸水组中CYFRA21-1含量明显高于腺癌和小细胞癌(P<0.01);小细胞癌胸水组中NSE和Pro-GRP含量明显高于腺癌和鳞癌(P<0.01)。CA125含量在胸水组中腺癌、鳞癌含量明显高于小细胞癌(P<0.01)。5 种标志物单项及联合检测的灵敏度肺癌胸水组均高于肺癌血清组,肺癌胸水中5项联合检测后灵敏度可达99.11%。结论:肺癌组胸水中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物联合检测有利于良恶性胸水的鉴别诊断,联合检测可以提高肺癌诊断的灵敏度,当肿瘤标志物显著升高时,CEA可作为肺腺癌的肿瘤标志物;CYFRA21-1可作为肺鳞癌的肿瘤标志物;NSE和Pro-GRP可作为小细胞癌的肿瘤标志物;CA125可作为非小细胞肺癌的肿瘤标志物。 相似文献
19.
Ardizzoni A Cafferata MA Tiseo M Filiberti R Marroni P Grossi F Paganuzzi M 《Cancer》2006,107(12):2842-2849
BACKGROUND: The authors assessed the predictive and prognostic role of decline in the serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) during chemotherapy in patients with advanced nonsmall cell lung cancer (NSCLC). METHODS: Changes in serum levels of CEA and CYFRA 21-1 during first-line, conventional chemotherapy were studied prospectively with an immunometric assay at baseline and every 2 courses in 117 patients with advanced NSCLC. Data were correlated with radiologic objective response (OR) and survival. RESULTS: One hundred seven patients were evaluable for radiologic and serologic response assessment after 2 chemotherapy courses. The radiologic OR rate was 44% overall. The CEA and CYFRA 21-1 responses (> or =20% reduction over baseline level; assessed after the second course of chemotherapy) were 38% and 61%, respectively. Statistically significant correlations were observed between CEA and CYFRA 21-1 responses and OR (P = .01 and P = .004, respectively). The median survival from response assessment (landmark analysis) was 9 months. In a univariate analysis, disease stage, performance status, baseline lactate dehydrogenase level (LDH), OR, CEA response, and CYFRA 21-1 response were correlated significantly with survival. In particular, the median survival was 13 months for patients who had a CEA response and 11 months for patients who had a CYFRA 21-1 response compared with 8 months and 6 months for patients who did not respond, respectively. In a multivariate analysis, performance status (P = .005), baseline LDH level (P = .02), CEA response (P = .03) and CYFRA 21-1 response (P = .01) were confirmed as independent prognostic factors for survival. CONCLUSIONS: CEA and CYFRA 21-1 responses appeared to be reliable surrogate markers of chemotherapy efficacy in patients with advanced NSCLC. 相似文献
20.
目的:探讨血清SCC-Ag、CYFRA21-1、LDH联合检测对肺鳞癌与肺部感染鉴别诊断的价值。方法:回顾性分析2017年1月至2018年3月北京市和平里医院消化科及呼吸科住院或门诊就诊的110例患者,其中肺鳞癌患者55例,肺部感染患者55例,使用化学发光法和速率法分别检测血清CYFRA21-1、SCC-Ag、LDH表达水平,以及肺鳞癌患者Ⅰ-Ⅳ期CYFRA21-1、SCC-Ag表达水平,经统计学处理后对比分析。结果:肺鳞癌组患者血清CYFRA21-1高于肺部感染组患者,差异有统计学意义(P<0.05);同时肺部感染组患者血清SCC-Ag表达高于肺鳞癌组,有统计学差异(P<0.05);Ⅰ期、Ⅱ期肺鳞癌组患者血清CYFRA21-1较Ⅳ期患者相比差异显著,随着肿瘤的进展,血清CYFRA21-1、SCC-Ag均有上升的趋势;肺鳞癌组患者血清LDH表达水平显著高于肺部感染组患者(P<0.01)。结论:独立的每个肿瘤标志物因其自身的特异性和敏感性,可能导致诊断的局限性,血清CYFRA21-1、SCC-Ag、LDH联合检测对肺鳞癌与肺部感染辅助鉴别诊断可能具有一定临床价值。 相似文献